MYXOID LIPOSARCOMA
Clinical trials for MYXOID LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new MYXOID LIPOSARCOMA trials appear
Sign up with your email to follow new studies for MYXOID LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer vaccine combo targets tough tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called PeptiCRAd-1, a virus-based cancer vaccine, combined with the immunotherapy drug pembrolizumab. The goal is to see if this combination is safe and can boost the immune system to fight several types of solid tumors, including mela…
Matched conditions: MYXOID LIPOSARCOMA
Phase: PHASE1 • Sponsor: Valo Therapeutics Oy • Aim: Disease control
Last updated May 17, 2026 02:58 UTC
-
Last-Resort access: experimental cell therapy offered to sarcoma patients
Disease control AVAILABLEThis program gives patients with synovial sarcoma or myxoid liposarcoma access to a cell therapy called TECELRA® when their prescribed batch doesn't meet quality standards. It's for people who cannot get a new batch made or undergo another cell collection. The goal is to provide …
Matched conditions: MYXOID LIPOSARCOMA
Sponsor: USWM CT, LLC • Aim: Disease control
Last updated May 17, 2026 02:57 UTC
-
New combo therapy aims to halt rare cancer growth
Disease control Recruiting nowThis study tests whether two drugs, mirdametinib and palbociclib, can safely control advanced liposarcoma that has spread or cannot be removed by surgery. About 54 adults with this rare cancer will receive different doses to find the best balance of safety and effectiveness. The …
Matched conditions: MYXOID LIPOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Experimental drug aims to revive failing cancer fighters in rare sarcomas
Disease control Recruiting nowThis early study tests a drug called N-803 in 8 people with rare soft-tissue sarcomas (synovial sarcoma or myxoid/round cell liposarcoma) whose cancer grew after a prior cell therapy. N-803 is an immune-boosting protein that may help the body's remaining cancer-fighting cells wor…
Matched conditions: MYXOID LIPOSARCOMA
Phase: EARLY_PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC